Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Day And Multiple Day Ascending Dose Study To Evaluate The Safety And Pharmacokinetics Of Orally Administered ARRY-371797 In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Emprumapimod (Primary)
- Indications Ankylosing spondylitis; Cancer; Dental pain; Musculoskeletal pain; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- 23 Apr 2012 Actual patient number 40 added as reported by ClinicalTrials.gov.
- 09 Feb 2009 New source identified and integrated (ClinicalTrials.gov): planned end date is now 1 Jan 2009.
- 25 Nov 2007 New trial record.